Skip to main content
OpenTrials
Completed

NCT Number: NCT05489380

Optical Diagnosis Versus Laser Measurement of Polyps' Size During Colonoscopy and Implications for Surveillance

Recent updates of the guidelines on polyp surveillance of the American Society of Gastrointestinal Endoscopy (ASGE) and European Society of Gastrointestinal Endoscopy (ESGE) increasingly focus on size of polyps as an important indicator of malignant transformation to colorectal cancer (CRC). However, the interobserver variability in polyp size assessment between optical diagnosis of endoscopists and pathologists is considerable. This may lead to incorrect surveillance intervals in patients at risk for developing colorectal cancer, which may increase the risk of post-colonoscopy CRC (PCCRC). This study aims to assess the precision of a new laser-based measurement system (AccuMeasure, VTM Technologies Ltd.) for polyps during colonoscopy.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Radboud university medical center, Nijmegen, Gelderland, Netherlands

Loading trial locations.

About this study

Objective: The main objective is to compare the precision of polyp size measurement by AccuMeasure to biopsy forceps assisted measurement. Secondary objectives are to assess: Time needed for measurement and learning curve, endoscopists advised surveillance intervals based on both measurement methods, and safety.

Study design: Multicenter, randomized, parallel group, endoscopist blinded study, including the measurement of 138 polyps during standard colonoscopy. With a polyp detection rate of approximately 40%1, this results in up to 345 patients/colonoscopies to be included. Enrollment will conclude once 138 polyps are included in the study.

Study population: All adult patients with screening or surveillance colonoscopies will be asked for informed consent. Polyps smaller than 25mm found during colonoscopy are considered eligible for inclusion. Up to 3 polyps per patient can be included in this study.

Intervention: Optical assessment will be performed upon identification of the polyp. Then, measurement with AccuMeasure and biopsy forceps will be performed in a randomized order. The endoscopist will remain blinded to the AccuMeasure measurement outcomes, to avoid a learning effect that could influence subsequent measurements.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • • Adult patients (>18 years)
  • Scheduled for screening, surveillance, or diagnostic colonoscopy
  • Polyps of all forms ≤ 25mm as assessed by the endoscopist

Exclusion criteria

  • • Therapeutic colonoscopy;
  • Inflammatory bowel disease (IBD);
  • American Society of Anesthesiologists (ASA) score of >3;
  • Inadequately corrected anticoagulation disorder or anticoagulation medication use;
  • Inability to provide informed consent;
  • Inadequate bowel preparation (Boston bowel preparation scale score [BBPS] <2 per segment);
  • No polyps identified during colonoscopy or only small (<5mm) hyperplastic rectal polyps;
  • Intraprocedural complications, not caused by the study device.

Treatment and study plan

AccuMeasure

Device

intracolonoscopy measurement of polyps using a laser-based device

Other names: laser-based polyp measurement

Primary outcomes

  1. Cohens' Kappa coefficient

    Time frame: at colonoscopy

    interobserver agreement between AccuMeasure and biopsy forceps assisted measurement

Secondary outcomes

  1. Number of Participants with adverse events up to 30 days post colonoscopy

    Time frame: 30 days post colonoscopy

    Number of Participants with adverse events

  2. Absolute size differences

    Time frame: at colonoscopy

    Size differences for optical/biopsy forceps/AM assessment as compared to pathology size measurement;

  3. Time for measurement

    Time frame: at colonoscopy

    Time for measurement with AccuMeasure related to number of measurements performed

  4. Endoscopist advised surveillance interval

    Time frame: At colonoscopy

    Endoscopist advised surveillance interval based on optical assessment during colonoscopy, on measurement with an open biopsy forceps, and on measurement with AccuMeasure

Other outcomes

  1. Method of polyp removal

    Time frame: at colonscopy

    method of polyp removal, i.e., polypectomy, endoscopic mucosal resection, endoscopic submucosal dissection

  2. BBPS

    Time frame: at colonoscopy

    Boston bowel preparation scale score (BBPS), in which segmental scores of 0 are worst and scores of 3 are best (completely clean)

Sponsors and collaborators

Lead sponsor

Radboud University Medical Center

Other

Collaborators

  • Bnai Zion Medical Center
  • Erasmus Medical Center
  • Indiana University Health
  • NYU Langone Health
  • Tel-Aviv Sourasky Medical Center

Registry information

Official study title

Optical Diagnosis Versus Laser Measurement of Polyps' Size During Colonoscopy and Implications for Surveillance (Polyp Size Study)

Important dates

Study start
2023
Primary completion
2025
Study completion
2026
First posted
Aug 5, 2022
Registry last updated
Mar 3, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.